Objective To observe the clinical efficacy and safety profile of febuxostat and allopurinol in patients with hyperuricemia and gout.Methods A total of 90 patients with hyperuricemia and gout were randomly divided into three groups:treatment group A,treatment group B and control group.There were 30 patients in each group.The control group was given oral allopurinol tablets 300 mg tid.The treatment group A was given oral administration of febuxostat tablets 35 mg qd,while the treatment group B was given oral administration of febuxostat tablets 70 mg qd.All groups were treated for 24 weeks.The clinical efficacy and the incidence of adverse drug reactions were compared among the three groups,and serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and uric acid were compared at baseline,12 weeks and 24 weeks of treatment.Results After treatment,the total effective rates were 56.67％ (17 cases/30 cases),66.67％ (20 cases/30 cases) and 46.67％ (14 cases/30 cases) in the treatment group A,the treatment group B and the control group,the difference was statistically significant (P ＜0.05);After 12 weeks of treatment,serum sICAM-1 in the treatment group A and treatment group B were (445.76 ± 135.85),(421.28 ± 122.25) and (493.39 ± 121.27) ng · mL-1;After 24 weeks,serum sICAM-1 of the treatment group A,the treatment group B and the control group were (387.71 ±126.75),(360.85 ± 125.50) and (441.45 ± 122.48) ng · mL-1;After 12 weeks of treatment,uric acid levels in the treatment group A and treatment group B were (445.57 ± 135.50),(460.60 ± 140.45) and (515.20 ± 142.15) ng · mL-1;After 24 weeks,uric acid levels of the treatment group A,the treatment group B and the control group were (425.10 ± 126.28),(410.10 ± 130.38) and (478.80 ± 164.72) ng · mL-1,the difference was statistically significant (all P ＜ 0.05);Statistically significant differences were found among the three groups before and after treatment (all P ＜ 0.05).There were no obvious adverse drug reactions in the two treatment groups and the control group.Conclusion Febuxostat can reduce the levels of serum slCAM-1 and uric acid in patients with hyperuricemia and gout,achieving better clinical efficacy than allopurinol

OBJECTIVETo determine the prevalence of sleep disordered breathing (SDB) in elderly patients with chronic congestive heart failure (CHF) and explore the relations between SDB and left ventricular function.

METHODSBy means of polysomnography, 56 elderly patients with CHF were divided into non-SDB, mild SDB, moderate SDB, and severe SDB groups, and the left ventricular ejection fraction (LVEF) was measure by (99)Tc equilibrium radionuclide angiography.

RESULTSIn the 56 elderly patients with CHF, 38 (67.9%) had SDB, including 12 (21.4%) mild SDB, 14 (25.0%) moderate SDB, and 12 (21.4%) severe SDB patients. Thirty (53.6%) of the 56 patients with CHF had obstructive sleep apnea (OSA), 4 (7.1%) had central sleep apnea and 22 (39.2%) had mixed sleep apnea. The moderate and severe SDB groups had lower minimum arterial oxyhemoglobin saturation during sleep than the non-SDB groups, and the apnea-hyponea index was closely related to LVEF (r=-0.74, P<0.01).

CONCLUSIONThe prevalence of SDB, predominantly OSA, is high in elderly patients with CHF. Moderate and severe SDB might affect the left ventricular function in these patients, who require polysomnography monitoring.

Aged ; Aged, 80 and over ; China ; epidemiology ; Chronic Disease ; Female ; Heart Failure ; complications ; physiopathology ; Humans ; Male ; Middle Aged ; Polysomnography ; Sleep Apnea Syndromes ; complications ; epidemiology ; Ventricular Dysfunction, Left ; physiopathology

By referring to the relevant ancient herbal literature， medical records and prescription books， the textual research of Violae Herba has been conducted to verify the name， origin， producing area， quality evaluation and processing method changes. The results showed that the name of Zihua Diding originated from its flower color and plant morphological characteristics. The primitive plant of Violae Herba is Viola genus of Violaceae， V. yedoensis， as stipulated in the 2020 edition of Chinese Pharmacopoeia， has been the mainstream in past dynasties of China. Violae Herba is mainly wild， and it is widely distributed throughout the country. Since modern times， the quality of Violae Herba is better with integrity， green color and yellow root. There are few records on the harvesting and processing methods of Violae Herba in ancient times， most of which are directly used after drying. It is suggested that the collection and processing methods of Violae Herba in the famous classical formulas can be implemented in accordance with the provisions of the 2020 edition of Chinese Pharmacopoeia.

OBJECTIVES: To investigate the clinical treatment outcomes and the changes of the outcomes over time in extremely preterm twins in Guangdong Province, China. METHODS: A retrospective analysis was performed for 269 pairs of extremely preterm twins with a gestational age of <28 weeks who were admitted to the department of neonatology in 26 grade A tertiary hospitals in Guangdong Province from January 2008 to December 2017. According to the admission time, they were divided into two groups: 2008-2012 and 2013-2017. Besides, each pair of twins was divided into the heavier infant and the lighter infant subgroups according to birth weight. The perinatal data of mothers and hospitalization data of neonates were collected. The survival rate of twins and the incidence rate of complications were compared between the 2008-2012 and 2013-2017 groups. RESULTS: Compared with the 2008-2012 group, the 2013-2017 group (both the heavier infant and lighter infant subgroups) had lower incidence rates of severe asphyxia and smaller head circumference at birth (P<0.05). The mortality rates of both of the twins, the heavier infant of the twins, and the lighter infant of the twins were lower in the 2013-2017 group compared with the 2008-2012 group (P<0.05). Compared with the 2008-2012 group, the 2013-2017 group (both the heavier infant and lighter infant subgroups) had lower incidence rates of pulmonary hemorrhage, patent ductus arteriosus (PDA), periventricular-intraventricular hemorrhage (P-IVH), and neonatal respiratory distress syndrome (NRDS) and a higher incidence rate of bronchopulmonary dysplasia (P<0.05). CONCLUSIONS There is a significant increase in the survival rate over time in extremely preterm twins with a gestational age of <28 weeks in the 26 grade A tertiary hospitals in Guangdong Province. The incidences of severe asphyxia, pulmonary hemorrhage, PDA, P-IVH, and NRDS decrease in both the heavier and lighter infants of the twins, but the incidence of bronchopulmonary dysplasia increases. With the improvement of diagnosis and treatment, the multidisciplinary collaboration between different fields of fetal medicine including prenatal diagnosis, obstetrics, and neonatology is needed in the future to jointly develop management strategies for twin pregnancy.
Bronchopulmonary Dysplasia/epidemiology* ; Female ; Gestational Age ; Humans ; Infant ; Infant, Extremely Premature ; Infant, Newborn ; Pregnancy ; Respiratory Distress Syndrome, Newborn/epidemiology* ; Retrospective Studies ; Treatment Outcome